Andean Precious Metals (APM) Scheduled to Post Earnings on Monday

Andean Precious Metals (CVE:APM - Get Free Report) is set to issue its quarterly earnings data after the market closes on Monday, November 11th.

Andean Precious Metals (CVE:APM - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported C$0.08 earnings per share for the quarter, hitting analysts' consensus estimates of C$0.08. Andean Precious Metals had a return on equity of 41.08% and a net margin of 23.75%. The firm had revenue of C$95.47 million during the quarter.

Andean Precious Metals Trading Down 4.8 %

Shares of APM stock traded down C$0.08 during mid-day trading on Monday, hitting C$1.57. The company's stock had a trading volume of 282,598 shares, compared to its average volume of 165,618. Andean Precious Metals has a 52 week low of C$0.55 and a 52 week high of C$2.18. The stock's fifty day simple moving average is C$1.44. The company has a market cap of C$234.50 million, a P/E ratio of 4.13 and a beta of 1.22.

Wall Street Analysts Forecast Growth

Separately, Desjardins upgraded Andean Precious Metals to a "moderate buy" rating in a research note on Thursday.

Insider Activity at Andean Precious Metals

In other news, insider 2176423 Ontario Ltd. bought 84,400 shares of the company's stock in a transaction on Tuesday, October 8th. The shares were purchased at an average price of C$1.51 per share, with a total value of C$127,359.60. Insiders have bought 1,202,800 shares of company stock valued at $1,607,032 over the last ninety days. Corporate insiders own 69.37% of the company's stock.

Andean Precious Metals Company Profile

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.